334 related articles for article (PubMed ID: 22408046)
41. The RTS,S malaria vaccine.
Casares S; Brumeanu TD; Richie TL
Vaccine; 2010 Jul; 28(31):4880-94. PubMed ID: 20553771
[TBL] [Abstract][Full Text] [Related]
42. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure.
Olotu A; Fegan G; Wambua J; Nyangweso G; Awuondo KO; Leach A; Lievens M; Leboulleux D; Njuguna P; Peshu N; Marsh K; Bejon P
N Engl J Med; 2013 Mar; 368(12):1111-20. PubMed ID: 23514288
[TBL] [Abstract][Full Text] [Related]
43. Plasmodium falciparum malaria vaccines in development.
Vekemans J; Ballou WR
Expert Rev Vaccines; 2008 Mar; 7(2):223-40. PubMed ID: 18324891
[TBL] [Abstract][Full Text] [Related]
44. Pre-erythrocytic malaria vaccines: towards greater efficacy.
Hill AV
Nat Rev Immunol; 2006 Jan; 6(1):21-32. PubMed ID: 16493425
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria.
Maire N; Shillcutt SD; Walker DG; Tediosi F; Smith TA
Value Health; 2011 Dec; 14(8):1028-38. PubMed ID: 22152171
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
Kester KE; McKinney DA; Tornieporth N; Ockenhouse CF; Heppner DG; Hall T; Krzych U; Delchambre M; Voss G; Dowler MG; Palensky J; Wittes J; Cohen J; Ballou WR;
J Infect Dis; 2001 Feb; 183(4):640-7. PubMed ID: 11170991
[TBL] [Abstract][Full Text] [Related]
47. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36.
Horii T; Shirai H; Jie L; Ishii KJ; Palacpac NQ; Tougan T; Hato M; Ohta N; Bobogare A; Arakaki N; Matsumoto Y; Namazue J; Ishikawa T; Ueda S; Takahashi M
Parasitol Int; 2010 Sep; 59(3):380-6. PubMed ID: 20493274
[TBL] [Abstract][Full Text] [Related]
48. Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities.
Birkett AJ; Moorthy VS; Loucq C; Chitnis CE; Kaslow DC
Vaccine; 2013 Apr; 31 Suppl 2():B233-43. PubMed ID: 23598488
[TBL] [Abstract][Full Text] [Related]
49. Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali.
Lyke KE; Dicko A; Kone A; Coulibaly D; Guindo A; Cissoko Y; Traoré K; Plowe CV; Doumbo OK
Vaccine; 2004 Aug; 22(23-24):3169-74. PubMed ID: 15297070
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan.
Mahmoudi S; Keshavarz H
Hum Vaccin Immunother; 2017 Sep; 13(9):2098-2101. PubMed ID: 28272979
[TBL] [Abstract][Full Text] [Related]
51. Further analysis of correlates of protection from a phase 2a trial of the falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults.
Olotu AI; Fegan G; Bejon P
J Infect Dis; 2010 Mar; 201(6):970-1. PubMed ID: 20170369
[No Abstract] [Full Text] [Related]
52. Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria.
Walther M
Expert Rev Vaccines; 2006 Feb; 5(1):81-93. PubMed ID: 16451110
[TBL] [Abstract][Full Text] [Related]
53. Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial.
Umeh R; Oguche S; Oguonu T; Pitmang S; Shu E; Onyia JT; Daniyam CA; Shwe D; Ahmad A; Jongert E; Catteau G; Lievens M; Ofori-Anyinam O; Leach A
Vaccine; 2014 Nov; 32(48):6556-62. PubMed ID: 25077418
[TBL] [Abstract][Full Text] [Related]
54. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
[TBL] [Abstract][Full Text] [Related]
55. RTS,S/AS01 Malaria Vaccine Efficacy is Not Modified by Seasonal Precipitation: Results from a Phase 3 Randomized Controlled Trial in Malawi.
Han L; Hudgens MG; Emch ME; Juliano JJ; Keeler C; Martinson F; Kamthunzi P; Tegha G; Lievens M; Hoffman IF
Sci Rep; 2017 Aug; 7(1):7200. PubMed ID: 28775306
[TBL] [Abstract][Full Text] [Related]
56. Malaria vaccine: a bright prospect for elimination of malaria.
Bairwa M; Rajput M; Khanna P; Rohilla R; Verma R; Chawla S
Hum Vaccin Immunother; 2012 Jun; 8(6):819-22. PubMed ID: 22739688
[TBL] [Abstract][Full Text] [Related]
57. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.
Neafsey DE; Juraska M; Bedford T; Benkeser D; Valim C; Griggs A; Lievens M; Abdulla S; Adjei S; Agbenyega T; Agnandji ST; Aide P; Anderson S; Ansong D; Aponte JJ; Asante KP; Bejon P; Birkett AJ; Bruls M; Connolly KM; D'Alessandro U; Dobaño C; Gesase S; Greenwood B; Grimsby J; Tinto H; Hamel MJ; Hoffman I; Kamthunzi P; Kariuki S; Kremsner PG; Leach A; Lell B; Lennon NJ; Lusingu J; Marsh K; Martinson F; Molel JT; Moss EL; Njuguna P; Ockenhouse CF; Ogutu BR; Otieno W; Otieno L; Otieno K; Owusu-Agyei S; Park DJ; Pellé K; Robbins D; Russ C; Ryan EM; Sacarlal J; Sogoloff B; Sorgho H; Tanner M; Theander T; Valea I; Volkman SK; Yu Q; Lapierre D; Birren BW; Gilbert PB; Wirth DF
N Engl J Med; 2015 Nov; 373(21):2025-2037. PubMed ID: 26488565
[TBL] [Abstract][Full Text] [Related]
58. Vaccines for preventing malaria (pre-erythrocytic).
Graves P; Gelband H
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006198. PubMed ID: 17054280
[TBL] [Abstract][Full Text] [Related]
59. Assessing the safety, impact and effectiveness of RTS,S/AS01
Praet N; Asante KP; Bozonnat MC; Akité EJ; Ansah PO; Baril L; Boahen O; Mendoza YG; Haine V; Kariuki S; Lamy M; Maleta K; Mungwira R; Ndeketa L; Oduro A; Ogutu B; Olewe F; Oneko M; Orsini M; Roman F; Bahmanyar ER; Rosillon D; Schuerman L; Sing'oei V; Terlouw DJ; Wéry S; Otieno W; Pirçon JY
Malar J; 2022 Apr; 21(1):132. PubMed ID: 35468801
[TBL] [Abstract][Full Text] [Related]
60. Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.
Galactionova K; Tediosi F; Camponovo F; Smith TA; Gething PW; Penny MA
Vaccine; 2017 Jan; 35(1):53-60. PubMed ID: 27890400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
